Periodontal disease initiation and progression occur as consequences of the host immune inflammatory response to oral pathogens. Periodontal pathogens produce collagenases and proteases that facilitate extracellular matrix degradation to produce nutrients for their growth (2) . In addition, Actinobacillus actinomycetemcomitans and other periodontal pathogens possess multiple virulence factors, such as leukotoxin, peptidoglycans, outer membrane proteins and LPS (20) , which initiate the host inflammatory response, including the production of host-derived inflammatory molecules such as matrix metalloproteinases (MMPs), cytokines and prostaglandins (6, 7, 20) . Although much effort has been applied in the analysis of lipopolysaccharide (LPS)-mediated destruction of the periodontium, little is known of the major intracellular signaling pathways utilized by A. actinomycetemcomitans LPS within resident periodontal tissue types.
Mitogen-activated protein kinases (MAPKs) are divided into three families, the extracellular signal-regulated kinases (ERK-1/2), c-jun N-terminal kinase (JNK) and p38a. Mitogens and growth factors primarily activate ERK-1/2, whereas the pro-inflammatory cytokines, such as interleukin-1b (IL-1b) and tumor necrosis factor-a (TNF-a), and cell stress-inducing factors, such as heat shock, ultraviolet radiation and oxygen radicals chiefly activate JNKs and p38a. The three MAPKs control the activation of many transcription factors, including AP-1 (homo-or heterodimer of the proteins c-fos and c-jun), nuclear factor-jB (NF-jB), or C/EBP (ccAAAT enhances binding protein).
It is assumed that all three MAPK families are expressed in diseased periodontal tissues, although expression levels may differ depending upon the cell types activated and the levels of inflammation. Within periodontally resident cells, including tissue macrophages and other periodontal cells, MAPKs are activated chiefly by LPS, IL-1 and TNF-a (18, 22, 27) . The p38 MAPK, most notably its p38a isoform, is activated mainly within cells involved in the inflammatory process. Activation of p38a through more proximal signaling intermediates termed MAPK kinases (MKK) induces synthesis of proinflammatory cytokines and prostanoids such as TNF-a, IL-1, IL-6, IL-8 and prostaglandin E 2 , via direct activation of gene transcription (8, 9, 14, 15, 21) . The p38a MAPK system can also increase cytokine production through post-transcriptional mechanisms of mRNA stabilization or translation through p38-MAPK-activated protein kinase 2 (MK2) stress-activated pathways (21, 32) . In addition, p38a MAPK controls the synthesis of other compounds, including chemokines, metalloproteinases and prostaglandins (16) . LPS-induced events leading to IL-6 production in periodontal ligament (PDL) cells has not been described. These studies indicate that although all MAPK pathways are involved in LPS-induced IL-6 production, p38a MAPK is the predominant MAPK required for maximal LPS-induced IL-6 expression.
Materials and methods

Cells and materials
Murine periodontal ligament (mPDL) fibroblasts immortalized with simian virus 40 large T antigen were obtained from Dr Martha Somerman (University of Washington, Seattle, WA). Stable mPDLs containing MKK-3 dominant-negative (DN) and MKK-6 DN mPDL stable cell lines were as described previously (22) . Mouse embryonic fibroblasts (MEF), both wildtype and p38a
)/) , were obtained by material transfer from Dr Angel Nebreda, Madrid, Spain. The p38a null MEFs were obtained by targeted deletion of the p38a ene and subsequent isolation of fibroblasts established from E11.5-E12.5 embryos (1). All cells were cultured with Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA) supplemented with 10% heat inactivated fetal bovine serum, 100 IU/ml penicillin, 100 lg/ml streptomycin in an incubator at 37°C in 5% CO 2 . IL-1b and Escherichia coli LPS were obtained from R & D Systems, Inc. (Minneapolis, MN) and Sigma Aldrich (St Louis, MO), respectively. The A. actinomycetemcomitans LPS serotype b was purified and obtained from strain Y4 as described elsewhere (29) (30) (31) . Biochemical inhibitors SB203580 (water-soluble), SP600125 (dimethyl sulfoxide [DMSO] soluble), and PD98059 (DMSO soluble) were obtained from Calbiochem (San Diego, CA). The final DMSO concentration used in all experimental protocols was 0.01% (v/v). Controls used included DMSO at the final concentration used to dissolve SP600125 and PD98059.
Immunoblot analysis
Whole cell lysates were harvested by scraping the cells on SDS sample buffer (62.5 mm Tris-HCl buffer pH 6.8, 10% glycerol, 50 mm dithiothreitol, 2% sodium dodecyl sulfate, 0.01% bromophenol blue) on ice, sonicated for 10 s and heat-denatured at 95°C for 5 min. Western blot analysis was performed as described previously (22) , proteins were separated on 10% Tris-HCl polyacrylamide gels run at 150 V for 50 min and subsequently electro-transferred for another 45 min at 32 mA in a semi-dry apparatus to nitrocellulose membranes. The membranes were blocked (Tris-buffered saline with 5% non-fat dry milk, 0.1% Tween-20) for 1 h at room temperature and then probed overnight at 4°C with primary antibodies. Primary antibodies for phosphorylated p38, JNK and ERK MAPK were from Cell Signaling (Danvers, MA), as well as the secondary horseradish peroxidase-conjugated antibodies. The GAPDH primary antibody was obtained from Chemicon (Temecula, CA). The presence of the primary antibodies was detected on radiographic film by using horseradish peroxidase-conjugated secondary antibody and a chemiluminescence system (Lumi-Glo, Cell Signaling).
Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was isolated from cells using TRIZOL (Invitrogen) according to the manufacturer's instructions. Total RNA was resuspended in Tris-ethylenediaminetetraacetic acid (TE, pH 7.0). RNA was quantified at an optical density of 260 nm (OD 260 ) using a Beckman DU-600 spectrophotometer. RT-PCR was used to analyse mRNA expression as described previously. Briefly, cDNA was synthesized by a RT kit (Applied Biosystems, Foster City, CA) using 300 ng total RNA in a 15 ll reaction. Each reaction contained 1.5 ll RT-buffer, 3.3 ll 25 mm MgCl 2 , 3 ll 10 mm dNTP, 0.75 ll oligo-dT, 0.3 ll RNAse inhibitor, 0.37 ll of Multiscribe reverse transcriptase, and 3.77 ll DNAse/ RNAse-free H 2 O. RT thermocycler conditions were as follows: 25°C for 10 min, 48°C for 30 min, and 95°C for 5 min. A 2-ll subsample of the RT product was then used in 25-ll PCR. The PCR mix contained nuclease-free water, 0.125 ll Taq polymerase, 1.5 mm MgCl 2 , 20 pm sense/ antisense primer, and 0.5 ll 12.5 mm dTNP. The PCR thermocycler (iCycler TM Thermocycler, BioRad, Hercules, CA) conditions used were as follows: 95°C for 5 min, and 35 cycles of 95°C for 1 min, 58°C (IL-6) or 52°C (glyceraldehyde-3-phosphate dehydrogenase [GAPDH]) for(accession no. NM_031168.1, forward 5¢-atgaagttcctctctgcaagagact-3¢ and reverse 5¢-cactaggtttgccgagtagatctc-3¢) and murine GAPDH (accession no. NM_008084, forward 5¢-caccatggagaaggccgggg-3¢and reverse 5¢-gacggacacattgggggtag-3¢). PCR products were run on a 1% agarose gel containing 0.5 lg/ml ethidium bromide. IL-6 levels were quantified and normalized to GAPDH levels using densitometric analysis on a BioRad Gel-Doc system and BioRad Quantity One Ò software.
Enzyme-linked immunosorbent assay (ELISA)
PDL cells were plated at 5 · 10 4 cells/well in 24-well dishes and stimulated with A. actinomycetemcomitans LPS (5 lg/ ml), E. coli LPS (5 lg/ml), or IL-1b (5 ng/ml) for 24 h. To determine the MAPK pathways involved, cells were pretreated for 1 h with SB203580, SP600125 and PD98059 (all at 10 lm) and stimulated. Vehicle-only and inhibitoronly cultures served as controls. Cell culture supernatants were harvested using an mIL-6 ELISA following the manufacturer's instructions (R & D Systems Inc.).
Statistical analysis
All data were subjected to statistical analysis through appropriate analysis parameters. Student's t-tests were used to obtain individual P-values when appropriate and two-way analysis of variance (anova) was used when multifactorial statistical analysis was needed. Two-way anova with Bonferroni post-tests and two-tailed paired Student's t-tests were performed using Graphpad Prism version 4.03 for Windows, Graphpad Software, San Diego, CA.
Results
MAPK pathways are rapidly activated in mPDL cells
Treatment with A. actinomycetemcomitans LPS, E. coli LPS and IL-1b resulted in phosphorylation of the ERK and p38 MAPK pathways (Fig. 1) ; A. actinomycetemcomitans LPS and IL-1b additionally activated JNK MAPK. These data indicate the rapid kinetics (within 10 min) of MAPK activation in mPDL cells.
Inflammatory stimuli induce IL-6 mRNA production in mPDL cells
Initial studies were conducted in mPDL cells to determine the time-course and dose-response of IL-6 mRNA expression in response to A. actinomycetemcomitans LPS, E. coli LPS, and IL-1b. Time-course of IL-6 mRNA induction experiments revealed that the optimal induction time for IL-6 mRNA was 18 h poststimulation ( Fig. 2A) . All inflammatory stimuli produced a bi-phasic induction of IL-6 mRNA, however, E. coli LPS and IL-1b induced similar temporal kinetic expression profiles of IL-6 mRNA. At the 18-h time-point the mean (n ¼ 3) fold induction of IL-6 was 2.7 with IL-1b (P ¼ 0.0267; paired t-test), 2.23 with E. coli LPS P ¼ 0.0055; paired t-test) and 2.01 with A. actinomycetemcomitans LPS stimulation (P ¼ 0.001; paired t-test). Consistent with the IL-6 mRNA levels, IL-6 protein expression increased in a similar timedependent manner (Fig. 2B) . At the 18-h and 24-h time-points, significant elevations in IL-6 protein were observed from time 0 in response to IL-1b, E. coli LPS and A. actinomycetemcomitans LPS stimulation (n ¼ 3). Dose-response analysis revealed the optimal stimulus concentration to be 5 lg/ml for both A. actinomycetemcomitans LPS and E. coli LPS while it was 5 ng/ml for IL-1b (n ¼ 3) (Fig. 2C) . Interestingly, A. actinomycetemcomitans and E. coli LPS 10 lg/ml provided saturated expression of IL-6 mRNA. This effect was also observed for IL-1b at 10 ng/ml. Optimal time and dose were utilized in all subsequent experiments.
MAPK signaling pathways involved in LPS-induced IL-6 expression
Next, we evaluated the MAPK signaling pathways involved in the induction of IL-6 production by IL-1b, E. coli LPS and A. actinomycetemcomitans LPS at the mRNA and protein levels. Major MAPK signaling pathways evaluated included ERK, JNK and p38a MAPK. The pathways were inhibited using specific biochemical inhibitors PD98059 (ERK), SP600125 (JNK) and SB203580 (p38 MAPK). The RT-PCR was performed on RNA isolated 18 h post treatment (n ¼ 3). SB203580 (10 lm) inhibited all inflammatory stimuli greatly, while SP600125 (10 lm) and PD98059 (10 lm) inhibition varied among inflammatory stimuli (Fig. 3A,B) . SB203580 was able to reduce IL-6 mRNA production by >70% for A. actinomycetemcomitans LPS treatment (P < 0.001; two-way anova), >95% for E. coli LPS treatment (P < 0.05; two-way anova, and 60% from IL-1b treatment (P < 0.05; two-way anova). SP600125 and PD98059 had the greatest inhibitory effects (50%; P < 0.05; two-way anova) with E. coli LPS and IL-1b treatments.
IL-6 ELISA was performed to determine if the effects of the biochemical inhibitors translated to the protein level (Fig. 4) . Murine PDL cells were treated as described above. Cell culture supernatants were harvested 24 h post-treatment and IL-6 ELISA was performed (n ¼ 4). Stimulation with each of the inflammatory stimuli produced copious IL-6 when compared to untreated cultures. Specifically A. actinomycetemcomitans LPS and IL-1b induced >500 pg/ml IL-6, while E. coli induced >450 pg/ml IL-6. SB203580 (p38 MAPK inhibitor) and SP600125 (JNK inhibitor) provided the greatest inhibition of inducible IL-6 production in response to inflammatory agonists. PD98059 (ERK inhibitor) provided comparable inhibition when cells were stimulated with E. coli LPS or IL-1b. B203580 (p38 MAPK inhibitor) reduced IL-6 production by all agonists by >60%, but the greatest decrease was observed in cells treated with A. actinomycetemcomitans LPS. The effect of SP600125 was observed mostly with E. coli LPS and IL-1bs the inhibitor reduced IL-6 production P70%. PD98059 was capable of inhibiting IL-1b-and E. coli LPS-induced IL-6, but was unable to inhibit A. actinomycetemcomitans LPSinduced levels equivalent to that of SB203580.
MKK-3/6-p38a MAPK pathway is required for IL-6 expression Biochemical inhibitors provide relatively specific inhibition of their respective signaling pathways. However, to verify the role of p38 MAPK in IL-6 production, stable mPDL cells over-expressing DN MKKs, which directly phosphorylate p38, were employed. MKK-3 and MKK-6 DN stable mPDL cells were utilized, along with mock-transfected (empty vector) mPDL cells (n ¼ 3). Cells were stimulated with A. actinomycetemcomitans LPS, E. coli LPS and IL-1b as described above (Figs 4B and 5A). Eighteen hours post stimulation, total RNA was isolated and IL-6 steady-state mRNA levels were measured. In MKK-3 DN cells IL-6 mRNA expression was statistically reduced in all stimulated cultures (P < 0.05 for A. actinomycetemcomitans LPS and P < 0.001 for E. coli LPS and IL-1b; two-way anova). MKK-6 DN cells significantly reduced the fold change of IL-6 mRNA in E. coli LPS (P < 0.01; two-way anova) and IL-1b only (P < 0.001; two-way anova). In both MKK-3 and MKK-6 DN cells, the greatest reduction of IL-6 mRNA was observed when cells were treated with IL-1b. These data suggest that while IL-1b and E. coli LPS activate p38 MAPKinduced IL-6 mRNA through MKK-3 and MKK-6, A. actinomycetemcomitans LPS activates p38 MAPK predominantly through MKK-3.
To further validate the need for an intact p38 signaling system for A. actinomycetemcomitans LPS-induced IL-6 expression, MEFs with targeted disruption of the p38a gene were used. The A. actinomycetemcomitans LPS induced over 300 pg/ml (P < 0.001) of IL-6 in wildtype MEFs while in p38a )/) MEFs, IL-6 production was not significant (P < 0.001) compared to the untreated controls (Fig. 6) . Lack of p38a reduced the amount of IL-6 induced by A. actinomycetemcomitans LPS by 90% (P < 0.001; two-way anova).
Discussion
Periodontal diseases are characterized by loss of alveolar bone, a process mediated by osteoclasts. Locally abundant LPS derived from gram-negative organisms is A B C Fig. 2 . IL-1b, Escherichia coli and Actinobacillus actinomycetemcomitans (Aa) LPS induce IL-6 mRNA. (A) Murine PDL cells were grown to near confluence and serum starved in 0.3% fetal bovine serum media for 6 h. Cells were then stimulated with A. actinomycetemcomitans LPS, E. coli LPS, and IL-1b for 2, 4, 8 and 18 h at doses as high as 10 ng/ml for IL-1b, and 10 lg/ml for both A. actinomycetemcomitans LPS and E. coli LPS. Total RNA was isolated and RT-PCR was performed measuring IL-6 normalized to GAPDH. Maximum IL-6 mRNA production plateaued at 5 ng/ml for IL-1b, and 5 lg/ml for both A. actinomycetemcomitans LPS and E. coli LPS. (B) Murine PDL cells were grown in the same manner as in (A) with cell culture supernatants harvested at the indicated time-points for IL-6 protein determination by ELISA. The results represent the mean pg/ml ± SE (n ¼ 3). Significant induction of IL-6 was observed at 18 and 24 h (C). The results represent the mean fold induction ±SE (n ¼ 3) for both panels. P-values were obtained using paired two-tailed Student's t-tests. P-values were derived comparing stimulant to control (no treatment), *P < 0.05 was considered statistically significant. largely responsible for the increased resorption of bone. LPS can stimulate the production of osteoblastic IL-1b, TNF-a, IL-6 and receptor activator of NF-kB ligand (RANKL) directly or indirectly (11, 13, 19) . Sources of IL-6 in the periodontium include periodontal and gingival fibroblasts, macrophages, lymphocytes and osteoblasts (25, 26) . However, the PDL fibroblast is poised in position to play a significant role in IL-6 production in chronic periodontitis. Inhibition of IL-6 expression presents an attractive target for the treatment of chronic inflammatory bone disease states. Thus, understanding IL-6 regulation in PDL fibroblasts may be critical for inflammatory-cytokine-based therapies in the management of periodontal diseases. In this report, MAPK signaling pathways induced by LPS that were required for IL-6 expression in PDL fibroblasts were analysed through biochemical inhibitors, MKK DN stable cell lines, and p38 knock-out cell models. The data indicate that A. actinomycetemcomitans LPS induction of IL-6 uses multiple MAPK pathways but predominantly the MKK-3-p38 pathway in mPDL fibroblasts.
Numerous studies have analysed periodontal pathogens and their constituents to produce pro-inflammatory cytokines. Extracts from A. actinomycetemcomitans have been able to induce IL-8 in gingival epithelial cells independent of LPS (24) . Comparison studies evaluating the ability of E. coli LPS and Porphyromonas gingivalis to induce IL-6, IL-8, IL-10 and IL-12 in dendritic cells found E. coli LPS to be the more potent agonist (12) . In the present study, the prototypical E. coli LPS was used as a relative comparison to A. actinomycetemcomitans LPS. Along with E. coli, the A. actinomycetemcomitansderived LPS has been demonstrated to induce IL-1b, IL-6 and TNF-a in human monocytes (3).
Our results support other studies that have shown a similar plateau in IL-6 expression by E. coli LPS in monocytes and bone-marrow-derived macrophages (17, 18) . The A. actinomycetemcomitans LPS also had the same kind of response as E. coli LPS. This effect may emphasize a conserved mechanism of activation during LPS-induced inflammation. Although IL-6 mRNA production was statistically significant as early as 2 h with A. actinomycetemcomitans LPS, E. coli LPS and IL-1b, maximal steady-state IL-6 expression was not reached until 18 h in mPDL cells. The ability of inflammatory stimuli to induce IL-6 after 2 h suggests that there is direct stimulation of IL-6 because de novo protein A B Fig. 3 . IL-6 requires predominantly p38a MAPK when stimulated by IL-1b, Actinobacillus actinomycetemcomitans (Aa) and Escherichia coli LPS. Murine PDL cells were grown to near confluence and serum starved with 0.3% FBS media for 6 h. Cells were pretreated with inhibitors specific for ERK (PD98059), JNK (SP600125), and p38a MAPK (SB203580) pathways at a concentration of 10 lm and stimulated with IL-1b (5 ng/ml) and LPS (5 lg/ml) from A. actinomycetemcomitans and E. coli. Total RNA was harvested after 18 h and RT-PCR was performed measuring IL-6 fold induction compared to GAPDH. Using two-way anova, P-values were derived comparing stimulant to control (no treatment), *P < 0.05 was considered statistically significant. Fig. 4 . p38a MAPK and JNK pathway are needed for Actinobacillus actinomycetemcomitans (Aa) LPS secretion of IL-6. Murine PDL cells were grown to near confluence then serum starved with 0.3% fetal bovine serum media for 6 h. Cells were treated with inhibitors and after 1 h cells were treated with inflammatory stimuli as described in Fig. 2 . Twenty-four hours after treatment, supernatants were collected and ELISA detection of IL-6 protein was measured. The results represent the mean pg/ml ± SE (n ¼ 3). Two-way anova was utilized to generate P-values. P-values compare inhibitor to stimulant (no inhibitor), *P values compare stimulant to control (no treatment), or *P<0.05 was considered statistically significant. synthesis has not occurred. At 18 h, IL-6 may be stimulated by multiple cytokines, acting in an autocrine manner, thus indirectly activating and amplifying inflammatory stimulus-induced IL-6 expression.
Surprisingly, when PDL cells were treated with biochemical inhibitors alone, the data indicate that SP600125 (the JNK inhibitor) significantly increased IL-6 mRNA induction when compared to vehicle control. In previous experiments, we have observed that SP600125 (JNK inhibitor) and PD98059 (ERK inhibitor) increase basal phosphorylated p38 MAPK levels in mPDL cell lysates (22) . IL-6 mRNA appeared to be induced predominantly through p38 MAPK for all inflammatory stimuli. However, p38 and JNK appeared to be equally involved in A. actinomycetemcomitans LPS secretion of IL-6. All biochemical inhibitors reduced IL-1b and E. coli LPS-induced IL-6 secretion. The discrepancies observed between IL-6 mRNA and protein inhibition are most likely the result of differences in IL-6 protein and mRNA half-lives (14) .
The present study evaluated only the contribution of MAPK towards LPSinduced IL-6 expression; however, IL-6 contains AP-1 (activator protein 1) and NF-IL-6 transcription factor binding regions, which directly implicates NF-jB in the production of IL-6. In the light of this, we cannot rule out the involvement of NFjB in the production of IL-6. Initial studies using a NF-jB inhibitor indicated partial inhibition of LPS-induced IL-6 (data not shown). In mouse fibrosarcoma cells, TNF-a-induced, NF-jB-stimulated IL-6 gene expression requires both p38a MAPK and ERK. When activated, p38a MAPK can activate NF-jB pathways through TNF receptor-associated factor-6 (27) . It is well established that p38 is phosphorylated by upstream kinases MKK-3 or MKK-6 (5). Dominant negative isoforms of both MKK-3 and -6 have been shown to have reduced kinase activity on p38a MAPK substrates (4).
The A. actinomycetemcomitans LPS preferentially utilized MKK-3/p38a activation for IL-6 mRNA expression. Interestingly, preferential activation of p38a by either MKK-3 or MKK-6 has been observed by others. Inoue et al. observed that MKK-3 plays a greater role in cytokine and MMP expression in fibroblast-like synoviocytes from patients with rheumatoid arthritis (10) . Osmotic shock and TNF-induced expression of cytokines has been reduced in MKK-3 )/) MEF (33). Our group has recently shown that MKK-6/p38 is important for LPS-induced MMP-13 expression is mPDL fibroblasts (Carlos Rossa, Jr., Paul M. Bronson, Min Liu, Keith L. Kirkwood, unpublished data). However, in the present study IL-1b and E. coli LPS utilized both MKK-3 and MKK-6 pathways with no statistically significant preference between either MKK.
One limitation of our stable cells is that either MKK-3 DN or MKK-6 DN is expressed, not both. As a consequence of blocking MKK-3 or MKK-6 activation of p38a MAPK can still occur through MKK-3 or MKK-6 phosphorylation. To address this, the role of p38a in A. actinomycetemcomitans LPS induction of IL-6 was extended with the use of MEF wild-type and p38a )/) MEF cells were grown plated and grown to near confluence. Cells were then serum starved with 0.3% fetal bovine serum media for 6 h followed by treatment with Actinobacillus actinomycetemcomitans LPS (5 lg/ml). After 24 h, supernatants were isolated and ELISA was performed measuring IL-6 protein. The results represent the mean pg/ ml ± SE (n ¼ 3). Two-way anova was utilized to generate P-values. P-values compare wildtype to p38a MAPK )/) MEF3T3 cells. *P-values compare stimulant to control (no treatment), or *P < 0.05 was considered statistically significant. cantly reduced when compared to wild-type cells, suggesting that p38a is a vital signaling intermediate required for IL-6 expression. Interestingly, E. coli LPS was unable to induce IL-6 protein expression in either wild-type or p38a
)/) cells but IL-1b effects were similar to those observed with A. actinomycetemcomitans LPS (data not shown). An additional limitation is that the data presented are from using p38 )/) MEF cells, which are clearly not PDL cells. PDL cells cannot be obtained from p38 )/) mice because these mice die in utero. The MEF cells were harvested between E11.5-12.5 and PDL tissue fibers that support the tooth and bone form approximately day 27 postconception, so PDL cells from the p38
mice cannot be obtained (M. Somerman, personal communication).
In summary, A. actinomycetemcomitans LPS-induced IL-6 expression requires p38a MAPK pathway signaling in PDL fibroblasts. IL-6 is a key pro-inflammatory cytokine capable of stimulating osteoclastogenesis in coupled bone turnover via induction of RANKL. Our group has recently established that TNF-a and IL-1b-induced RANKL in bone marrow stromal cells requires p38 MAPK (23) . Importantly, parathyroid hormone and 1,25(OH) 2 -vitamin D 3 -induced RANKL are unaffected by p38 inhibitors, supporting the role of p38 antagonists to block inflammation-stimulated bone loss while sparing physiological bone turnover. Thus, because p38 MAPK is a key signaling intermediate utilized by LPS and IL-1-induced IL-6 expression in PDL fibroblasts, targeting p38 MAPK may have therapeutic importance for the management of chronic periodontitis.
